Actelion's Macitentan Meets Primary Endpoint In Pivotal SERAPHIN Study, Approval Filings Expected In Fourth Quarter

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".